SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-059771
Filing Date
2023-11-07
Accepted
2023-11-07 07:30:31
Documents
76
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20230930.htm   iXBRL 10-Q 3007444
2 EX-31.1 verv-ex31_1.htm EX-31.1 18194
3 EX-31.2 verv-ex31_2.htm EX-31.2 18169
4 EX-32.1 verv-ex32_1.htm EX-32.1 10244
5 EX-32.2 verv-ex32_2.htm EX-32.2 10201
  Complete submission text file 0000950170-23-059771.txt   9384158

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20230930_def.xml EX-101.DEF 198828
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20230930_lab.xml EX-101.LAB 472159
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20230930_pre.xml EX-101.PRE 340084
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20230930_cal.xml EX-101.CAL 43020
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20230930.xsd EX-101.SCH 61803
70 EXTRACTED XBRL INSTANCE DOCUMENT verv-20230930_htm.xml XML 1573017
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 231381572
SIC: 2834 Pharmaceutical Preparations